Cambrex Licenses Cell Lines to Chugai Pharmaceutical Co.

05-Oct-2005

Cambrex Bioscience Walkersville, Inc., a subsidiary of Cambrex Corporation, announced that they have signed an evaluation license agreement with Chugai Pharmaceutical Co., Ltd. for the use of certain Cambrex Clonetics® Conditionally Immortalized cell lines. The licensed cell lines were created using a clone of a specially modified large T antigen and licensed telomerase technology.

Under the terms of the agreement, Chugai has access to two conditionally immortalized cell lines for use in their pharmaceutical drug discovery programs. Further financial details of the agreement are not disclosed.

Cambrex is conducting several concurrent programs to conditionally immortalize cell types critical to understand and manage metabolic disease: muscle cells for diabetes; adipose cells for obesity; endothelial cells for heart disease; hepatocytes for toxicology studies. Conditionally immortalized cells can be generated in volumes sufficient for high throughput screening (HTS), are homogenous and express normal markers similar to primary cells, thus managing the key limitations of primary cells in drug discovery. Conditional immortalization allows cells to divide indefinitely, retain normal function and appearance, and produce uniform cell populations for functional cell-based assays and long-term gene expression studies. Availability of these cell lines will speed drug discovery by allowing researchers to focus on the most promising drug candidates, while eliminating the poor candidates earlier in the process.

https://www.bionity.com/en/news/49337/cambrex-licenses-cell-lines-to-chugai-pharmaceutical-co.html